Canada markets close in 12 minutes

Resverlogix Corp. (RVX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.98000.0000 (0.00%)
As of 3:44PM EST. Market open.
Full screen
Previous Close0.9800
Open0.9800
Bid0.9700 x 0
Ask0.9900 x 0
Day's Range0.9500 - 0.9800
52 Week Range0.5600 - 1.5300
Volume74,177
Avg. Volume49,063
Market Cap229.307M
Beta (5Y Monthly)0.31
PE Ratio (TTM)61.25
EPS (TTM)0.0160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Resverlogix Announces Update Webcast and Conference Call

    CALGARY, Alberta, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today announced that on January 28th, 2021 at 10:00 am MT, it will be hosting a webcast and conference call for the purpose of updating stakeholders regarding three key areas: Closing details of the previously announced private placement by Sheikh Abdulgader Aboud Baeshen, President and CEO of Baeshen Trade, Abdulgader Baeshen Co.,BETonMACE2 design upgrades and partnering options, andCOVID-19 trial update and apabetalone’s strong antiviral effect For those wishing to join the January 28th event, it is highly recommended to access the webcast over the Internet using the following LINK. If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or +1-403-351-0324 (International Toll). Callers should dial-in at least 10 min prior to the scheduled start time. About Resverlogix Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). Follow us on: Twitter: @Resverlogix_RVXLinkedIn: https://www.linkedin.com/company/resverlogix-corp-/ For further information please contact: Investor RelationsEmail: ir@resverlogix.comPhone: 403-254-9252Or visit our website: www.resverlogix.com This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to the anticipated completion of a private placement, BETonMACE2, a COVID-19 trial, partnering and the potential role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease, other orphan diseases and COVID-19. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

  • Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
    GlobeNewswire

    Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure

    Cardiovascular Publication Explores the Prespecified BETonMACE Analysis on Hospitalization for Heart Failure Following Acute Coronary SyndromeCALGARY, Alberta, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study”, in the high-impact, peer-reviewed Cardiovascular Diabetology. The publication can be viewed using the following LINK.“In this prespecified analysis from the BETonMACE study, significantly fewer hospitalizations for heart failure (HHF) in patients with type 2 diabetes and a recent history of acute coronary syndrome (ACS) were observed in the apabetalone treatment group compared to placebo,” said Dr. Stephen J. Nicholls of Monash University, member of the BETonMACE Clinical Steering Committee, and lead author of the paper.“The unprecedented reduction in heart failure seen in BETonMACE further demonstrates the broad benefit these patients receive from apabetalone treatment,” said Donald McCaffrey, President and CEO of Resverlogix. “In agreement with the US Food and Drug Administration (FDA) – following receipt of the Company’s Breakthrough Therapy Designation announced on February 3, 2020, we will be including HHF in the composite primary endpoint for our upcoming registration-enabling study, BETonMACE2.”Publication Highlights include: * BETonMACE was the first, and only, Phase 3 clinical trial to evaluate the cardiovascular efficacy and safety of a BET protein inhibitor * Apabetalone treatment, in a pre-specified analysis, was associated with a 41% hazard reduction for first hospitalization for heart failure compared to placebo (p=0.03) with qualitative evidence of an early and progressive separation in events between the two groups * When total hospitalizations for heart failure were analyzed, apabetalone treatment demonstrated a significant 53% hazard reduction (p=0.01) * The combination of either first hospital admission for heart failure or cardiovascular death occurred less frequently in apabetalone than placebo-treated patients (28% hazard reduction, p=0.04) * Following 24 weeks of apabetalone treatment, a statistically significant increase in high-density lipoprotein (HDL) (15.4%; p<0.0001) and decrease in alkaline phosphatase (ALP) (-8.31%; p<0.0001) was observed compared to the placebo group * These findings contribute to apabetalone’s beneficial effect on cardiovascular outcomes observed in BETonMACEPublication Background and Conclusions:Despite current standard of care treatment options, patients with diabetes and ACS have a high risk of experiencing subsequent cardiovascular events, including those related to congestive heart failure. This prespecified analysis, illustrated that treatment with apabetalone following an ACS was associated with a lower incidence of hospital admission for heart failure. This finding provides the rationale to further explore apabetalone’s effect on HHF and highlights a potential new therapeutic strategy to benefit these high-risk patients. Previously reported BETonMACE details can be found using the following LINK.  About ResverlogixResverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).Follow us on: * Twitter: @Resverlogix_RVX * LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/For further information please contact:Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: www.resverlogix.comThis news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to the Company’s registration-enabling study – BETonMACE2 – and the potential role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

  • Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
    GlobeNewswire

    Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen

    CALGARY, Alberta, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected six (6) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:                                Votes ForVotes WithheldPercent ForPercent Withheld Donald J. McCaffrey126,867,2442,046,35898.41%1.59% Norma Biln128,231,386682,21599.47%0.53% Shawn Lu127,276,1401,637,46298.73%1.27% Kelly McNeill127,223,6871,689,91498.69%1.31% Siu Lun (Dicky) To128,404,864508,73899.61%0.39% Kenneth Zuerblis128,242,687670,91499.48%0.52% Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated November 9, 2020 (the “Information Circular”). The Information Circular is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.A webcast archive of the executive presentation portion of the Meeting will be available HERE no later than 7:00 pm MT today.$13 Million Investment by Sheikh Abdulgader Aboud Baeshen Further to the Company’s announcement on October 6, 2020 regarding a $13 million private placement, shareholders of the Company have voted over 99% in favor of the private placement and, following discussions today, the strategic investor from Saudi Arabia, Sheikh Abdulgader Aboud Baeshen, President and CEO of Baeshen Trade, Abdulgader Baeshen Co., has confirmed completion of his due diligence, including an independent review performed by a highly-regarded international advisory firm, and his commitment to proceed with his investment.  “We are pleased with our discussions with Resverlogix and its entire team and believe in the recent Breakthrough Therapy Designation granted by the FDA; Apabetalone and its effect on cardiovascular, CKD, Alzheimer’s and COVID-19 as well as its contribution to the future of mankind,” said Sheikh Abdulgader. About ResverlogixResverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).Follow us on: * Twitter: @Resverlogix_RVX * LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/For further information please contact:Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: www.resverlogix.comThis news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information related to the anticipated completion of a private placement and the potential role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.